

Head Injury update Committee meeting 15

Date: 22/11/2022

Location: Virtual meeting

Minutes: Confirmed

Committee members present:		
Caroline Balson [CB]		(Present for notes 1 – 6)
Ian Bernstein [IB] – Chair		(Present for notes 1 – 6)
Fiona Lecky [FL]		(Present for notes 1 – 6)
Emily Feilding [EF]		(Present for notes 1 – 6)
Adel Helmy [AH]		(Present for notes 1 – 6)
Catriona Jones [CJ]		(Present for notes 1 – 6)
Virginia Newcombe [VN]		(Present for notes 1 – 6)
Patrick O’Halloran [PO]		(Present for notes 1 – 6)
James Piercy [JP]		(Present for notes 1 – 6)
Gillian Richards [GR]		(Present for notes 1 – 6)
Matthew Wiles [MW]		(Present for notes 1 – 6)
Colin Williamson [CW]		(Present for notes 1 – 6)

Co-opted members present:		
Indi Banerjee [IB]		(Present for notes 1 – 5)
Clara O’Brien [CO]		(Present for notes 1 – 5)
Barry Seemungal [BS]		(Present for notes 1 – 5)

In attendance:		
Helen Barnett [HB]	Senior Editor	(Present for notes 1 – 6)
Rupert Franklin [RF]	Guideline Commissioning Manager	(Present for notes 1 – 6)
Sharangini Rajesh [SR]	Senior Systematic Reviewer	(Present for notes 1 – 6)
Sharon Swain [SS]	Guideline Lead	(Present for notes 1 – 6)
David Wonderling [DW]	Head of Health Economics	(Present for notes 1 – 6)
Giulia Zuodar [GZ]	Project Manager	(Present for notes 1 – 6)
Gill Ritchie [GR]	Guideline Lead	(Present for notes 1 – 6)

4.0.03 DOC Cmte minutes

Jean MacKershan [JMK]	Content Manager (BNF)	(Present for notes 1 – 6)
-----------------------	-----------------------	---------------------------

Apologies:

Mark Lyttle [ML]	GC member
Curtis Offiah [CO]	GC member

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the fifteenth meeting on Head Injury (update). ML and CO sent apologies.

The Chair outlined the objectives of the meeting, which included the following:

- Presenting the stakeholder comments and any proposed edits to the recommendations

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion covered the entire guideline scope.

3. Declarations of interest

The Chair and a senior member of the Developer's team confirmed that based on previously recorded declarations the following applies:

FL is partially excluded from the Tranexamic acid review. FL can stay in the meeting but not participate in the discussion of the recommendations.

FL and VN are partially excluded from the review on clinical and cost effectiveness of pre-hospital strategies to convey people with head injury to a distant specialist neuroscience centre. FL and VN can stay in the meeting but not participate in the discussion of the recommendations.

FL is partially excluded from the Indications for imaging review (children). FL can stay in the meeting but not participate in the discussion of the children recommendations.

FL is partially excluded from the Indications for imaging for subgroups review (anticoagulant or antiplatelet therapy). FL can stay in the meeting but not participate in the discussion of the recommendations.

FL, VN and PO are partially excluded from the Biomarkers for post-concussion review. FL, VN and PO can stay in the meeting but not participate in the discussion

4.0.03 DOC Cmte minutes

of the recommendations.

FL and VN are partially excluded from the Biomarkers for predicting brain injury complications review. FL, VN and PO can stay in the meeting but not participate in the discussion of the recommendations.

VN is partially excluded from the review on how long people with head injury who are on anticoagulant or antiplatelet therapy should be observed in hospital after normal brain imaging or no indication for early imaging. VN can stay in the meeting but not participate in the discussion of the recommendations.

FL is partially excluded from the reviews on indications for hospital admission in people with small intracranial injuries and on rate of clinical deterioration in people with isolated skull fracture. FL can stay in the meeting but not participate in the discussion of the recommendations.

The Chair asked the committee to declare any new interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
IB	Chair	Reviewer for an article "Multi-Center Study Evaluating Factors Associated with Treatment Outcome for Low Back Pain Injections" submitted for publication in BMJ Medicine. Reviewers' comments and accreditation are published alongside the article.	Non-specific, professional and personal	No action other than the process of open declaration

4. Minutes of the previous meeting

The Committee agreed that the minutes of the previous meeting were an accurate record of the meeting.

5. Review stakeholder comments and recommendations

The committee discussed and edited the recommendations.

FL was partially excluded from the Tranexamic acid review. FL stayed in the meeting but did not participate in the discussion of the recommendations.

FI and VN were partially excluded from the review on clinical and cost effectiveness

4.0.03 DOC Cmte minutes

of pre-hospital strategies to convey people with head injury to a distant specialist neuroscience centre. FL and VN stayed in the meeting but did not participate in the discussion of the recommendations.

FL was partially excluded from the Indications for imaging review (children). FL stayed in the meeting but did not participate in the discussion of the children recommendations.

FL was partially excluded from the Indications for imaging for subgroups review (anticoagulant or antiplatelet therapy). FL stayed in the meeting but did not participate in the discussion of the recommendations.

FL, VN and PO were partially excluded from the Biomarkers for post-concussion review. FL, VN and PO stayed in the meeting but did not participate in the discussion of the recommendations.

FL and VN were partially excluded from the Biomarkers for predicting brain injury complications review. FL, VN and PO stayed in the meeting but did not participate in the discussion of the recommendations.

VN was partially excluded from the review on how long people with head injury who are on anticoagulant or antiplatelet therapy should be observed in hospital after normal brain imaging or no indication for early imaging. VN stayed in the meeting but did not participate in the discussion of the recommendations.

FL was partially excluded from the reviews on indications for hospital admission in people with small intracranial injuries and on rate of clinical deterioration in people with isolated skull fracture. FL stayed in the meeting but did not participate in the discussion of the recommendations.

6. Any other business

None.